Previous 10 | Next 10 |
Collegium Pharmaceutical (COLL) provides its FY2021 guidance as follows:Xtampza ER revenues expected to be in the range of $155-$165MNucynta franchise revenues in the range of $175-$185M.Adj. EBITDA (excluding stock-based compensation) is expected in the range of $160-$170M.Tot...
– Xtampza ® ER Revenues Expected in the Range of $155.0 million to $165.0 million – – Nucynta ® Franchise Revenues Expected in the Range of $175.0 million to $185.0 million – – Adjusted EBITDA Expected ...
Collegium Pharmaceutical recently reported their Q3 earnings with a beat on EPS and revenue. Despite some serious COVID-19 headwinds, Collegium was able to record another quarter of growth and increase their cash on hand while paying down debt. I believe the company has laid the g...
Collegium Pharmaceutical, Inc. (COLL) Q3 2020 Earnings Conference Call November 06, 2020 4:30 PM ET Company Participants Alex Dasalla - Head of Investor Relations Joe Ciaffoni - Chief Executive Officer Paul Brannelly - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Conference...
Image source: The Motley Fool. Collegium Pharmaceutical Inc (NASDAQ: COLL) Q3 2020 Earnings Call Nov 6, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: Collegium Pharmaceutical Inc (COLL) Q3 2020 Earnings Call Trans...
– Strengthened Formulary Access for Xtampza ® ER, Including Exclusive National Medicare Part D Win – – Generated $34.2 Million in Cash Flow from Operations – – Adjusted EBITDA of $41.8 Million – ...
[[AAXN]], [[ACLS]], [[ADT]], [[AGO]], [[AIG]], [[AINV]], [[ALRM]], [[ALTR]], [[AMCR]], [[AMH]], [[AMN]], [[ANGI]], [[APPN]], [[ATGE]], [[ATRC]], [[AVLR]], [[AYX]], [[AZPN]], [[BFAM]], [[BGS]], [[BHF]], [[BIGC]], [[BILL]], [[BKNG]], [[BLDP]], [[BMRN]], [[BNFT]], [[CABO]], [[CARG]], [[CDAY]], [...
Collegium Pharmaceutical (NASDAQ:COLL) is scheduled to announce Q3 earnings results on Wednesday, November 4th, after market close.The consensus EPS Estimate is $0.90 (+600.0% Y/Y) and the consensus Revenue Estimate is $77.39M (+6.1% Y/Y).Over the last 1 year, COLL has beaten EPS estimates 50...
STOUGHTON, Mass., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced a publication titled, “Postmarketing Analysis of Misuse, Abu...
Collegium Pharmaceuticals (NASDAQ: COLL) and Athenex (NASDAQ: ATNX) may not be the most popular stocks on the market in terms of media coverage, but both might just make you rich with a well-timed investment. Unlike many of their compatriots in the world of small market cap ...
News, Short Squeeze, Breakout and More Instantly...
Collegium Pharmaceutical Inc. Company Name:
COLL Stock Symbol:
NASDAQ Market:
Collegium Pharmaceutical Inc. Website:
2024-07-20 16:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-10 14:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...